New therapeutic target molecules for gastric and gastroesophageal junction cancer
International Journal of Clinical Oncology · 2024-09 · 29 (9) · 1228-1236
DOI: 10.1007/s10147-024-02521-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 17.04.2024. Verfasst von Hisato Kawakami. Beteiligte Einrichtung: Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-sayama, 589-8511, Japan. kawakami_h@med.kindai.ac.jp. Hauptthemen laut MEDLINE: Stomach Neoplasms, Esophagogastric Junction, Molecular Targeted Therapy, Esophageal Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
Molecularly targeted therapy for receptor tyrosine kinases (RTKs) has faced limitations in gastric and gastroesophageal junction (G/GEJ) cancer except for HER2-targeted agents, possibly due to inappropriate assay selection that has hindered identification of sensitive patients, in addition to coexisting genetic abnormalities as well as intratumoral heterogeneity. Immunohistochemistry of RTKs has, thus, proved largely unsuccessful for patient selection, and detection of RTK gene amplification as a true oncogenic driver is problematic given the small numbers of affected individuals. FGFR2 amplification is associated with poor prognosis in G/GEJ cancer, and immunohistochemistry of the FGFR2b protein isoform has proved effective for the detection of such FGFR2-dependent tumors. Phase III and Ib/III trials of the FGFR2-targeted antibody bemarituzumab for G/GEJ cancer overexpressing FGFR2b are ongoing based on the promising result in a phase II trial, especially in cases with an FGFR2b positivity of ≥ 10%. Challenges to EGFR- and MET-targeted therapies are being tackled with antibody-drug conjugates (ADCs) and bispecific antibodies. CLDN18.2 is expressed in some G/GEJ tumors but lacks oncogenic driver potential, and the CLDN18.2-targeted antibody zolbetuximab prolonged the survival of CLDN18.2-positive G/GEJ cancer patients in phase III trials. Antibody-drug conjugates and ADCs that target CLDN18.2 are also being pursued for treatment of such patients. Similarly, targeting of nondriver molecules such as DKK1, TROP2, and CEACAM5 is under investigation in early-stage clinical trials. This shift in focus from target molecules with driver potential to markers for precise drug delivery should increase the number of possible targets in G/GEJ cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-higashi, Osaka-sayama, 589-8511, Japan. kawakami_h@med.kindai.ac.jp.
Zitieren
APA
Kawakami, H. (2024). New therapeutic target molecules for gastric and gastroesophageal junction cancer. International Journal of Clinical Oncology, 29(9), 1228-1236. https://doi.org/10.1007/s10147-024-02521-3
Vancouver
Kawakami H. New therapeutic target molecules for gastric and gastroesophageal junction cancer. International Journal of Clinical Oncology. 2024;29(9):1228-1236. doi:10.1007/s10147-024-02521-3
BibTeX
@article{Kawakami2024,
author = {Kawakami, Hisato},
title = {New therapeutic target molecules for gastric and gastroesophageal junction cancer},
journal = {International Journal of Clinical Oncology},
year = {2024},
volume = {29},
number = {9},
pages = {1228--1236},
doi = {10.1007/s10147-024-02521-3}
}
EUVIMED